All Articles

Denver’s Cherry Creek North is booming, and The Broe Group is doubling down with a new $200M project, despite a challenging office market. Here’s how they plan to win.

The Rumphius Foundation’s recent grants to grassroots organizations are making a tangible difference in communities, addressing critical needs from childhood support to basic necessities. A deep dive into the impact.

The LegalTech Breakthrough Awards recognized Clarra for its case management platform as the industry pivots towards AI-powered solutions and robust data residency features to navigate global compliance.

Clinical-stage biotech Domain Therapeutics bolsters its leadership with a new CMO as it progresses novel immuno-oncology therapies targeting G protein-coupled receptors. The company's lead candidate, DT-7012, is currently in Phase I/II trials.

From MLB stars to YouTube creators, the 2025 Chris Greicius Award recipients exemplify a growing trend: philanthropic engagement reshaping the landscape of children’s charities. A deeper look at the impact.

Aesthetic device company Rohrer Aesthetics launches a program to support small businesses, reinvesting sales into the community and awarding $5,000 grants. Learn how this initiative impacts the growing aesthetic market.

Lightspeed Commerce taps ex-Medallia & Contentsquare executive Gabriel Benavides as its new CRO, signaling a sharpened focus on streamlining operations and accelerating growth in key markets.

Vivani Medical is advancing its ultra-long-acting semaglutide implant, potentially offering a once- or twice-yearly alternative to daily injections for chronic weight management. The company is gearing up for Phase 1 trials and securing funding amidst a booming GLP-1 market.

Phase 3 data for Imunon's IL-12 gene therapy, IMNN-001, signals potential breakthrough in treating advanced ovarian cancer. Can this novel approach overcome the challenges of existing therapies and deliver a much-needed clinical benefit?

RTX’s Pratt & Whitney opens a new European Technology & Innovation Center in the Netherlands, joining the race to decarbonize air travel with hybrid-electric and hydrogen propulsion technologies. A deep dive into the competitive landscape and Dutch ecosystem.

Neurvati Neurosciences, backed by Blackstone Life Sciences, appoints Carlos Martin as CCO, signaling a strategic shift towards early commercialization for its pipeline, notably Radiprodil for GRIN-NDD. This move highlights a growing trend of private equity investment in neuroscience.

Positive Phase 2a data and a strengthened financial position position Q32 Bio as a potential disruptor in the alopecia areata space, offering hope for a condition with limited effective therapies.

PR Newswire asserts leadership in AI-driven press release visibility. An in-depth look reveals a competitive landscape where multiple players are investing heavily in AI, raising questions about true differentiation.

A veteran real estate firm is doubling down on social impact with the launch of LegacyFirst, a new company dedicated to transforming underutilized properties into engines of economic prosperity. The move signals a growing trend in mission-driven investment.

With the first proton therapy system in the Greater Bay Area, Hong Kong’s HKSH Medical Group is positioning itself as a leader in advanced cancer treatment and attracting international patients.

Positive Phase 2 results for vidofludimus calcium offer a potential breakthrough in progressive multiple sclerosis, but the biotech faces a critical funding challenge to bring the therapy to market.

A new partnership between Brightstar Lottery and Allwyn aims to revitalize instant ticket games with innovative technology. The move reflects a broader industry shift toward enhanced player engagement and digital integration.

Direct-to-consumer epigenetic testing is booming, promising insights into biological age and health risks. But experts raise questions about accuracy, interpretation, and whether the science truly delivers on its promises.

Press release giant PR Newswire asserts dominance in search visibility and AI integration, citing data showing double the traffic and mentions of key competitors. How is the company adapting to a rapidly evolving media landscape?

Despite a Q3 revenue dip, Protalix BioTherapeutics is prioritizing pipeline development, particularly its novel gout treatment, PRX-115, and navigating a competitive landscape for Gaucher disease therapies. Analysts watch closely.